Abstract
Objective: To test the feasibility of using a computerized device called the Med-eMonitor for daily monitoring of medication compliance and symptoms; (o enhance medication and research protocol compliance: and to educate schizophrenic patients and their families. Method: Outpatients with schizophrenia were assessed for psychiatric symptoms, quality-of-life, and demographic information. They were instructed in (lie use of the Med-eMonitor. A test of knowledge about schizophrenia wat administered. Over the two-month course of the study, the patient and ‘or caregiver used the monitor at home to take medication, answer questions about symptoms and signs, and learn educational facts about the disease and medication. Medication compliance and symptom data were uploaded each day from the Med-eMonitor to an internet-enabled database, where investigators could log on, monitor patients, and program devices. At the end of the study, patients and caregivers filled out a satisfaction scale, and a test of knowledge about schizophrenia. Treating physicians also rated their satisfaction. Results: Twenty-two patients and 16 caregivers completed informed consent. All were able to learn to use the Med-eMonitor in the clinic. Fourteen (64%) patients used the monitor at home. There was no significant difference in demographic variables. level of symptoms, or other clinical measures between the patients who did and did not use the device at home. Patients had nonsignificant improvement from pre- to post-test on the educational quiz (t=−1.25; p =.23) Caregivers showed significant improvement (t = −2.59; p =.048). Most patients, caregivers, and physicians were satisfied with using the Med-eMonitor system. Discussion: The Med-eMonitor System provided for compliance enhancement with medications and protocols, ease of central evaluation by treating professionals, additional education, and reduced onsite evaluation in chronic schizophrenics. Results suggest (hut use of computerized devices is feasible in daily clinical monitoring and treatment of schizophrenia. Patients, caregivers, and clinicians found the Med-eMonitor to be useful, easy to use, satisfying, and educational.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carpenter WT, Hanlon TE. Heinrichs DW. et al. Continuous versus targeted meditation in schizophrenic outpatients: outcome results. Am J Psychiatry. 1990:147(9): 1138–1148.
Gaebel W, Janner M, Frommann N, el al. First versus multiple episode schizophrenia: two year outcome of intermittent and maintenance medication strategies. Schizopherenia Research 2002; 53(1–2): 145–159.
Doering S, Muller P. Kopcke. el al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophrenia Bull, 1998:24(1):87–98.
Buchanan RW. Kirkpatrick B. Summerfelt A. el al. Clinical predictors of relapse following neuroleptic withdrawal. Biological Psychiatry. 1992: July 1: 32(1):72–78.
Marder SR. Wirshing WC. Van Pullen T, el al. Fluphenazine versus placebo supplementation for prodromal signs of relapse in schizophrenia. Arch General Psychiatry. 1994:51 (4):280–287.
Jones RB, Atkinson JM, Coia DA. et al. Randomised trial of personalized computer based information for patients with schizophrenia. Br Med J. 2001:322(7290):835–840.
Cramer A. Relationship between medication compliance and medical outcomes. Am J Health Syst Pharm. 1995; 52 (14 Suppl 3):S27–29.
Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits, Arch Int Med. 1990:150(7): 1509–1510.
Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet. 1997;32 (5): 345–356.
Matsui D, Hermann C, Brando M, et al. Clinical use ill the Medication Event Monitoring System: a new window into pediatric compliance. Clin Pharmacol Ther. 1992:52(1): 102–103.
Matsuyama JR, Mason BJ. Jue SG. Pharmacists’ interventions using an electronic medication-event monitoring device’s adherence data versus pill counts. Ann Pharmacother. 1993;27(7–8):851–855
First MB, Spitzer RL, Gibbon M, el al. User’s Guide for the Structured Clinical Interview for DSM-IV. Axis 1 Disorders. Washington. DC: American Psychiatric Press: 1996.
Folstein MF, Folstein SE, McHugh PR. Minintental state: A practical method for grading the cognitive stale of patients for the clinician. J Psychiatr Res. 1975:12:189–198.
Amador XF, Strauss DM. The Settle to Assess Unawareness of Mental Disorder. New York: Columbia University and New York Slate Psychiatric Institute; 1990.
Overall JE. Gorham DR. The Brief Psychiatric Rating Scale, Psychol Rep. 1962: 10:799–802.
Andreasan NC, Olsen S. Negative versus positive schizophrenia: Definition and validation. Arch General Psychiatry. 1982:39:789–794.
Lehman AF. A quality of life interview for the chronically mentally ill. Evatuat Program Plan. 1988:11:51–62.
Endicott J, Spitzer RL Fleiss JL, Cohen J. The global assessment scale. Arch General Psychiatry. 1976:33:766–772.
Herz MI, Melville C, Relapse in schizophrenia. Am J Psychiatry. 1980:137:801–805.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ruskin, P.E., Wende, J.V.D., Clark, C.R. et al. Feasibility of Using the Med-eMonitor System in the Treatment of Schizophrenia: A Pilot Study. Ther Innov Regul Sci 37, 283–291 (2003). https://doi.org/10.1177/009286150303700304
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286150303700304